Beyond the lab: antibodies
Supported by:
Published: 24 October 2024
Share this post
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
This report provides insights into the latest breakthroughs in antibody research, from cancer research to neuroscience.
Download now to read more about:
Targeting CD40 with bispecifics to outsmart tumours by Søren Bregenholt, Chief Executive Officer of Alligator Bioscience
Discover a novel approach in cancer immunotherapy using bispecific antibodies. Alligator Bioscience has shown success with their monospecific CD40 antibody, mitazalimab, particularly in treating pancreatic cancer. This bispecific antibody approach offers a targeted, potent immune activation that addresses tumours’ immune evasion mechanisms, particularly in cancers with poor T-cell infiltration.
Leveraging agonist antibodies to address immunological diseases by Dr Judy Chou, CEO, President and Board member at AltruBio, Inc
Learn how agonist antibodies show potential as a novel therapeutic approach in immunological diseases, helping to mediate interactions between circulating immune cells and influencing the intensity and duration of inflammatory responses.
Combining precision bispecific antibodies with targeted radiotherapy by Alexander Schinagl, co-founder and Chief Technology Officer of OncoOne
Radioimmunotherapy (RIT) is a promising cancer treatment gaining recognition in precision oncology. It utilises radiolabelled antibodies to deliver targeted radiation to tumours, with success in haematologic cancers. However, its use in solid tumours has been limited by off-target radiation and toxicity, with few clinical trials advancing beyond phase II.
Detecting antibodies unique to stage I and II melanoma patients by Ellen Capon at Drug Target Review
A new method, using tumour-specific profiling to detect antibodies unique to stage I and II melanoma patients, was presented1 at the European Academy of Dermatology and Venerology (EADV) Congress 2024, which could greatly improve both diagnosis and prognosis.
Promising effect of anti-CADM1 antibody on neuronal activity by Ellen Capon at Drug Target Review
Researchers at Kindai University in Japan investigated the effect of anti-CADM1 antibodies on neuronal activity, with their findings likely to open a new field of long-acting analgesics, offering hope for a safer pain-relieving strategy.